EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Booster mRNA Vaccination Prevents Breakthrough Severe COVID‐19 Infections

Harika Öykü Dinç iD, Hayriye Kirkoyun Uysal iD, Günay Can iD, Beyhan Budak iD, Ferhat Osman Daşdemir iD, Elif Keskin iD, Okan Aydoğan iD, İlker İnanç Balkan iD, Rıdvan Karaali iD, Suat Saribaş iD, Sevgi Ergin iD, Neşe Saltoğlu iD und 1 weitere

Journal of Medical Virology · 2026-06 · 98 (6)

DOI: 10.1002/jmv.71026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 18.06.2026. Verfasst von Harika Öykü Dinç und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Faculty of Medicine, Üsküdar University, Istanbul, Turkey. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Immunization, Secondary, BNT162 Vaccine. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IUC Scientific Research Projects Unit.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to assess the humoral immune response following administration of a BNT162b2 mRNA COVID‐19 booster dose and to evaluate its association with the development of SARS‐CoV‐2 infection after vaccination. Between July 2021 and February 2022, serum samples were collected from 313 individuals 28 days after receiving a COVID‐19 booster dose. Quantitative SARS‐CoV‐2 IgG antibodies directed against the receptor‐binding domain (RBD) of the spike protein were measured using a chemiluminescent microparticle immunoassay. Neutralizing antibody activity, defined as inhibition of the RBD–ACE2 interaction, was evaluated semi‐quantitatively by a competitive ELISA. Participants were followed for 6 months after the final dose to identify confirmed SARS‐CoV‐2 infections. The cohort included 97 males (31%) and 216 females (69%), with a mean age of 39.43 years. The median SARS‐CoV‐2 IgG antibody level at day 28 was 7713.3 AU/mL, and the median neutralizing antibody inhibition rate was 99.2%. Antibody levels were not significantly associated with age or comorbidities. Booster vaccination induced a strong humoral immune response in all participants. However, the occurrence of post‐vaccination infections despite high antibody levels suggests immune escape by emerging variants. While vaccines may not fully prevent infection, they provide substantial protection against severe disease and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Immunization, SecondaryBNT162 VaccineCOVID-19 VaccinesHumansFemaleMaleAntibodies, ViralImmunoglobulin GAdultAntibodies, NeutralizingMiddle AgedBreakthrough InfectionsSpike Glycoprotein, CoronavirusAgedImmunity, HumoralVaccines, Synthetic

Stichwörter der Autor:innen

BNT162b2COVID‐19ELISASARS‐CoV‐2antibody

Substanzen

Antibodies, ViralImmunoglobulin GAntibodies, NeutralizingBNT162 VaccineSpike Glycoprotein, CoronavirusCOVID-19 Vaccinesspike protein, SARS-CoV-2Vaccines, Synthetic

Autor:innen und Institutionen

  • Department of Medical Microbiology, Faculty of Medicine, Üsküdar University, Istanbul, Turkey.
  • Department of Medical Microbiology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Department of Public Health, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Medical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Medical Microbiology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.

ORCID-Profile: Harika Öykü Dinç, Hayriye Kirkoyun Uysal, Günay Can, Beyhan Budak, Ferhat Osman Daşdemir, Elif Keskin, Okan Aydoğan, İlker İnanç Balkan, Rıdvan Karaali, Suat Saribaş, Sevgi Ergin, Neşe Saltoğlu, Bekir Kocazeybek

Förderung

  • IUC Scientific Research Projects Unit

Zitieren

APA

Dinç, H. Ö., Uysal, H. K., Can, G., Budak, B., Daşdemir, F. O., Keskin, E., Aydoğan, O., Balkan, İ. İ., Karaali, R., Saribaş, S., Ergin, S., Saltoğlu, N., & Kocazeybek, B. (2026). Booster mRNA Vaccination Prevents Breakthrough Severe COVID‐19 Infections. Journal of Medical Virology, 98(6). https://doi.org/10.1002/jmv.71026

Vancouver

Dinç HÖ, Uysal HK, Can G, Budak B, Daşdemir FO, Keskin E, et al. Booster mRNA Vaccination Prevents Breakthrough Severe COVID‐19 Infections. Journal of Medical Virology. 2026;98(6). doi:10.1002/jmv.71026

BibTeX
@article{Din2026,
  author = {Dinç, Harika Öykü and Uysal, Hayriye Kirkoyun and Can, Günay and Budak, Beyhan and Daşdemir, Ferhat Osman and Keskin, Elif and Aydoğan, Okan and Balkan, İlker İnanç and Karaali, Rıdvan and Saribaş, Suat and Ergin, Sevgi and Saltoğlu, Neşe and Kocazeybek, Bekir},
  title = {Booster mRNA Vaccination Prevents Breakthrough Severe COVID‐19 Infections},
  journal = {Journal of Medical Virology},
  year = {2026},
  volume = {98},
  number = {6},
  doi = {10.1002/jmv.71026}
}
Kostenlos starten →